StockSelect from Equitymaster


VIEW SAMPLE REPORT | CUSTOMER REVIEWS

StockSelect aims to help you build a portfolio of solid, safe and profitable bluechip stocks. As a member you will receive our views on the various investment opportunities and our top recommendations in an exclusive report that is published on the last Friday of every month.
Each StockSelect Report Offers...
»  Equitymaster's view on the investment scenario
»  A new Blue Chip investment idea
»  Our selection of Top 5 bluechip stocks to buy
»  In-depth reviews of our open recommendations
As a member, you will also benefit from...

»  Our weekly Research Digest to help you keep track of all our latest research
»  24x7 access to our research and recommendations via our website
»  Exclusive Special Reports available from time-to-time only to our subscribers
»  Special-Features available exclusively to our subscribers
»  Our Premium Portfolio Tracker tool for free (worth Rs 330 per year) to track your portfolio
Where StockSelect Fits In...
Stock markets tend to be very volatile. And putting too much money in a single stock can be very risky. That is why we advise investors to have a well-diversified portfolio. In our view, large cap/ blue-chip stocks are the safest of the lot. Because of their large size, they may not grow as fast as small caps or mid caps. But they are relatively more stable and resilient to negative macroeconomic developments. This keeps them in good stead over the long term and makes them reliable wealth creators. According to us, large cap/ blue chip stocks should comprise at least 60% of your total equity portfolio. However, a single large cap/ blue-chip should not form more than 5-6% of your total portfolio. This is to make sure that even if a certain blue chip stock does not deliver as per expectations, the overall portfolio is not affected to a great extent.
Value for Money
1-year subscription only Rs 5,000*
SUBSCRIBE TODAY!
© Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Use of the information herein is at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual investors. Before acting on any recommendation, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: 91-22-6143 4055 CIN:U74999MH2007PTC175407
 
Member's Arena
Username 
Password 
Remember Username
Keep me signed in
(Please do not use this option on a public machine)
   (Forgot your password?)
New Member?
SUBSCRIBE TODAY!
7-day money back trial*
* Get a full refund if you are not happy with your subscription.You can request for a refund within 7 days of your subscription.


Recommend this page